Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia
- 1 November 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Sleep
- Vol. 30 (11), 1555-1561
- https://doi.org/10.1093/sleep/30.11.1555
Abstract
STUDY OBJECTIVES: To evaluate the efficacy and safety of doxepin 1, 3, and 6 mg in insomnia patients.DESIGN: Adults (18-64 y) with chronic primary insomnia (DSM-IV) were randomly assigned to one of four sequences of 1 mg, 3 mg, and 6 mg of doxepin, and placebo in a crossover study. Treatment periods consisted of 2 polysomnographic assessment nights with a 5-day or 12-day drug-free interval between periods. Efficacy was assessed using polysomnography (PSG) and patient-reported measures. Safety analyses included measures of residual sedation and adverse events.MEASUREMENTS AND RESULTS: Sixty-seven patients were randomized. Wake time during sleep, the a priori defined primary endpoint, was statistically significantly improved at the doxepin 3 mg and 6 mg doses versus placebo. All three doses had statistically significant improvements versus placebo for PSG-defined wake after sleep onset, total sleep time, and overall sleep efficiency (SE). SE in the final third-of-the-night also demonstrated statistically significant improvement at all doses. The doxepin 6 mg dose significantly reduced subjective latency to sleep onset. All three doxepin doses had a safety profile comparable to placebo. There were no statistically significant differences in next-day residual sedation, and sleep architecture was generally clinically preserved.CONCLUSIONS: In adults with primary insomnia, doxepin 1 mg, 3 mg, and 6 mg was well-tolerated and produced improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night. The side-effect profile was comparable to placebo, with no reported anticholinergic effects, no memory impairment, and no significant hangover/next-day residual effects. These data demonstrate that doxepin 1 mg, 3 mg, and 6 mg is efficacious in improving the sleep of patients with chronic primary insomnia.Keywords
This publication has 22 references indexed in Scilit:
- Sleep Maintenance Insomnia: Strengths and Weaknesses of Current Pharmacologic TherapiesAnnals of Clinical Psychiatry, 2006
- Wakefulness-inducing effects of histamine in the basal forebrain of freely moving ratsBehavioural Brain Research, 2004
- Cataplexy-Active Neurons in the Hypothalamus: Implications for the Role of Histamine in Sleep and Waking BehaviorNeuron, 2004
- Residual Effects of HypnoticsCNS Drugs, 2004
- Abuse and dependence potential for the non‐benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological dataAddiction, 2003
- The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomniaPsychopharmacology, 2003
- Doxepin in the Treatment of Primary InsomniaPublished by Physicians Postgraduate Press, Inc ,2001
- Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulationJournal of Neuroscience, 1993
- Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the ratJournal of Neural Transmission, 1986
- The effects of doxepin HCl on sleep and depression.1982